Younger Age Offers No Protection From HFrEF DeathsPatients aged 40-85 years with heart failure with reduced ejection fraction (HFrEF) died at higher rates over 5 years than matched peers from the general population across all age groups; however, the greatest relative impact was seen in younger adults (aged 40-49 years).
Atopic Dermatitis in Childhood Not Linked to Early Cardiovascular RiskIn a UK study of 9281 participants followed from childhood into early adulthood, atopic dermatitis, including more active and severe atopic dermatitis, was not consistently associated with cardiometabolic risk scores, traditional cardiovascular risk factors (blood pressure, lipid profiles), or measures of subclinical atherosclerosis.
Changes in Physical Activity Following Heart Failure in Humans and Animal Models: A Scoping ReviewAccording to a review, patients with heart failure (HF) experience decreased physical activity (PA) due to fatigue, shortness of breath, and psychological and environmental factors. This leads to a decline in physical function and prognosis, but the extent of the decline in PA specifically due to heart failure remains unclear.
Toward Personalized Heart Failure Management: Integrating Biomarkers and Multimodal Monitoring StrategiesScientists have discovered that effective treatment of heart failure (HF) requires timely detection and treatment of congestive heart failure in both inpatient and outpatient settings. As HF treatment approaches become more complex, interest in improved therapeutic strategies, including biomarker-based approaches and noninvasive and invasive remote monitoring methods, is growing.
Factor XI Inhibitor Abelacimab Cuts Bleeding Risk Across Age Groups in Atrial FibrillationAmong adults with atrial fibrillation (AF), those who received the factor XI inhibitor abelacimab had a lower risk for major or clinically relevant nonmajor bleeding than those who received the oral anticoagulant rivaroxaban across age groups, with greater absolute risk reductions in older adults.
RU
EN